Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 38 results:
Συντάκτης Τίτλος Τύπος [ Έτος![(Desc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-desc.png)
Φίλτρα: Συντάκτης is Koutras, Angelos [Clear All Filters]
(2011).
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012). Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study..
Oncol Rep. 27(1), 216-24.
(2012). Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel..
Anticancer Res. 32(10), 4569-80.
(2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy..
J Transl Med. 10, 10.
(2012).
(2012).
(2012).
(2013).
(2013).
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies..
BMC Clin Pathol. 14, 28.
(2014). The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014). Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer..
Clin Breast Cancer. 14(5), 330-8.
(2014).
(2014).
(2014). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study..
Histol Histopathol. 30(9), 1129-41.
(2015). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015). Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer..
Pharmacogenomics. 16(1), 79-94.
(2015).
(2015). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016). Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia..
Mol Clin Oncol. 4(2), 211-220.
(2016). MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer..
J Transl Med. 14(1), 136.
(2016).
(2016).
(2016).